CERS
CERUS CORP
NASDAQ · Healthcare · Medical - Devices · US
$2.49
+6.41%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$2.39
From 52W high−24.09%
Volume1.31M
Market cap$502.87M
P/E (TTM)—
P/S (TTM)2.2x
Div yield—
Key dataNov 4, 2026
Open
$2.39
From 52W high
−24.09%
Volume
1.31M
Market cap
$502.87M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
671.1x
P/E (TTM)
—
RSI (14)
54.1
MomentumView details →
1D Return
+6.41%
YTD Return
+18.20%
SummaryUpdated Sep 1, 2026
Cerus Corporation (NASDAQ:CERS) is a biomedical products company founded in 1991 and headquartered in Concord, California. The company went public in 1997 and has spent over three decades developing and commercializing blood safety technologies. Cerus operates as a specialized medical device company focused on pathogen reduction systems for blood transfusions, representing a critical niche within the broader healthcare industry. The company has evolved from a research-stage biotechnology firm into a commercial-stage enterprise with global operations, achieving its first profitable year in 2024 after years of development and market penetration efforts.
Similar companies
Latest newsMore news →
CERUS CORP announced financial results for the third quarter ended September 30, 2026.2d agoCERUS CORP announced that it will release its third-quarter 2026 financial results after the market close on November 2, 2026, and hold a conference call and webcast at 4:30 p.m. ET.16d agoCerus reported Q2 2026 results showing product revenue growth of 10%, a 7% decrease in operating expenses, and adjusted EBITDA more than tripling year-over-year.78d ago